Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

BioScience Health Innovations (BHIC) Gross Margin (2023 - 2026)

BioScience Health Innovations has reported Gross Margin over the past 4 years, most recently at 64.66% for Q1 2026.

  • Quarterly Gross Margin fell 837.0% to 64.66% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 54.29% through Mar 2026, down 1621.0% year-over-year, with the annual reading at 56.97% for FY2025, 1398.0% down from the prior year.
  • Gross Margin was 64.66% for Q1 2026 at BioScience Health Innovations, up from 36.36% in the prior quarter.
  • Over five years, Gross Margin peaked at 86.33% in Q2 2023 and troughed at 36.36% in Q4 2025.
  • The 4-year median for Gross Margin is 74.13% (2024), against an average of 71.15%.
  • The largest YoY upside for Gross Margin was -75bps in 2024 against a maximum downside of -2234bps in 2024.
  • A 4-year view of Gross Margin shows it stood at 77.89% in 2023, then dropped by -29bps to 55.56% in 2024, then plummeted by -35bps to 36.36% in 2025, then soared by 78bps to 64.66% in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Gross Margin are 64.66% (Q1 2026), 36.36% (Q4 2025), and 61.71% (Q3 2025).